"From Indigo to the World": Atelier Seiran to Present Talk Series at Venice Biennale Collateral Event

-Exploring Spirit and Creativity behind Centuries of Japanese Indigo Craftsmanship at Palazzo Dona dalle Rose-

TOKUSHIMA, Japan, Sept. 16, 2026 /PRNewswire/ -- Atelier Seiran, a Tokushima-based textile studio, will host a talk series titled "From Indigo to the World -- The Spirit and Creativity of Japanese Culture" on September 22 and 23, 2026, at Palazzo Dona dalle Rose. The event is part of the official Collateral Events program of the 61st Venice Biennale, within the exhibition "Fissures of Light Diaspora: Dissonances in Fa Minor."

The talks will explore the cultural philosophy behind Atelier Seiran's work, tracing how Japan's relationship with nature shapes its sense of beauty and creativity. Atelier Seiran was founded in Tokushima in 1970 by indigo artist Yoko Hashimoto, who devoted her career to Awa indigo and developed a distinctive method combining indigo dyeing with wax-resist (roketsuzome) techniques. Today, her daughters, Hatsuko Ukigawa and Kiyoko Hashimoto, carry that legacy forward, extending it into new forms of artistic expression.

Hatsuko Ukigawa, the studio's director, will speak at two sessions, presenting Atelier Seiran's work and its cultural context. The program will also spotlight "Les Lucioles" (The Fireflies), a collaborative piece created through Ukigawa's encounter with Cameroonian designer Serge Mouangue, reflecting the creative possibilities of Japanese indigo across cultures.

Images: https://kyodonewsprwire.jp/release/202609145806?p=images

"Venice has long been a crossroads where East and West meet," the studio said.

"Through indigo, we hope to open a new dialogue here -- one that shares not just a color, but the culture and spirit behind it."

Details: https://kyodonewsprwire.jp/attach/202609145806-O1-loHpqgd9.pdf

Event summary

-Title/Theme: From Indigo to the World -- The Spirit and Creativity of Japanese Culture

-Dates: Sept. 22-23, 2026, 2:00 PM-5:00 PM daily

-Venue: Palazzo Dona dalle Rose (Cannaregio 5038, Venice), within the official

Biennale Collateral Event "Fissures of Light Diaspora: Dissonances in Fa Minor"

-Organizers: Atelier Seiran; Fondazione Dona dalle Rose

-Partner: TISSALI Arts & Cultures

-Supporting sponsors (Planned): MetaMoJi Corporation; Shoshin Foundation; ExoEARTH Inc.

-Speakers: Hatsuko Ukigawa (Representative, Atelier Seiran); Chiara Modica Dona dalle Rose (Fondazione Dona dalle Rose, moderator, tentative)

-Featured in video: Yoko Hashimoto, Kiyoko Hashimoto, Serge Mouangue

For more information, visit: https://kyodonewsprwire.jp/release/202604227924

Atelier Seiran's work is currently on view as part of the official Venice Biennale 2026

Collateral Events program (through November 22).

Official website: https://seiran.art/english

Share this article

Barcelona launches HOWS Barcelona, a new congress on urban and affordable housing

BARCELONA, Spain, Sept. 16, 2026 /PRNewswire/ -- HOWS Barcelona – Housing World Summit , the new international congress on urban and affordable housing, will take place from 3 to 5 November at the Gran Via venue as part of Smart City Expo World Congress. The summit, which aims to lead the international debate on housing, one of the most pressing challenges facing cities today, is promoted by Barcelona City Council and organized by Fira de Barcelona. It will feature a three-day program with 20 sessions and over 100 speakers.

HOWS Barcelona will bring together all the stakeholders with the capacity to transform the housing sector, both nationally and internationally, including cities, housing providers, urban professionals, third sector and non-profit organizations, real estate developers, investors and academia. The event aims to become a leading platform for debate and innovation in urban housing, fostering solutions to the major challenges of contemporary housing.

The congress program will focus on five key themes: Urban Planning & Land Policy as tools to increase housing supply; Housing Regulation to deliver public and affordable housing; Building Innovation as a driver for accelerating housing delivery; Renovation, Retrofit & Reuse to improve the quality, and Social and Affordable Housing to drive a sustainable housing stock; and financing mechanisms to enable housing development and investment.

High-level summits

Additionally, HOWS Barcelona will host a series of high-level activities designed to strengthen political dialogue, international cooperation and the exchange of experiences between cities. These initiatives provide a meeting point for political leaders, mayors and housing policymakers to share best practices, explore common solutions and foster collaboration among cities.

The congress will also hold the Housing Mayors Meeting, a closed-door working session bringing together mayors and senior housing officials from international cities, as well as the Housing Mayors Roundtable, an open discussion featuring mayors and global urban leaders.

The Barcelona Housing and Renovation Forum (FHAR) into its program. Previously held as a standalone event over four editions, the forum will provide an opportunity to explore key issues such as expanding the supply of public housing, renovating both public and private housing stock, and housing market regulation.

HOWS is supported by the Government of Catalonia, the Spanish Ministry of Housing and Urban Agenda, the European Union, and is held in collaboration with organizations and institutions including the Barcelona Metropolitan Area (AMB), the European Investment Bank (EIB), C40 Cities, UN-Habitat, and Metropolis.

Share this article

Tridion Agent and Tridion Connect now in public preview, enabling enterprises to build, deploy and orchestrate AI agents within governed content workflows

MAIDENHEAD, England, Sept. 16, 2026 /PRNewswire/ -- RWS (AIM: RWS.L), a global AI solutions company, today announced the public preview of its Tridion agentic platform, giving regulated enterprises a governed way to build and run AI agents across their content lifecycle. The platform is built on Tridion, RWS's structured content platform, which is used across the medtech, pharmaceutical and manufacturing industries to manage complex technical and regulatory documentation.

Tridion Agent and Tridion Connect are designed to tackle a costly problem for organizations managing complex technical and regulatory information: when a regulation, standard or product specification changes, teams need to work out exactly what content is affected before they can update it.

The new agentic capabilities automate that process within Tridion. They can detect external changes, identify affected governed content and propose updates for human review – helping teams move from change detection to an approved response faster, without giving up control over what gets published.

Consider a new labeling requirement. Tridion Connect can identify the instructions for use and other documentation that may be affected across products and markets. Tridion Agent can then prepare proposed wording changes for a technical writer to review. Instead of manually cross-referencing a new requirement against large volumes of documentation, the team starts with the affected content and proposed changes already identified.

Connecting change to content

Tridion Connect brings signals from regulations, standards and other external sources directly into enterprise content workflows. When a relevant change occurs, it traces that change to governed content in Tridion, helping teams understand its potential impact and decide what needs attention.

Tridion Agent provides the framework for building, deploying and orchestrating specialist AI agents across Tridion. Agents work with governed content and approved sources, operate within defined workflows and maintain an audit trail of their activity.

This gives enterprises a way to put agentic AI to work on critical content while retaining the controls they already use to manage accuracy, consistency and compliance.

"We have spent several years building a structured content foundation on Tridion, so our documentation stays accurate, consistent and current in every market we serve. When RWS presented the agentic platform at Tridion Live Sessions, it matched the direction we already wanted to take: automation that acts on content we govern, with our people still making the decisions. We are excited to have been invited to join the preview, letting us help shape the platform rather than wait for it," commented Jenny Häggström, Technical Publications Systems Lead at Arjo.

From AI experiments to useful work

"Businesses don't need more AI experiments. They need AI that can do useful work with the information they trust," said David Alley, SVP Tridion at RWS.

"Connecting external change directly to governed enterprise content takes a lot of the manual work out of finding what's affected and preparing a response. People still make the decisions, but they have much better information to make them with.

"This is where agentic AI becomes genuinely useful for enterprises. Agents can act on trusted information within the workflows and controls organizations already rely on, rather than operating as another disconnected AI tool."

The launch extends Tridion's structured content foundation into agentic workflows, allowing organizations to build AI agents around the same content, governance and processes they already use to manage critical information.

In early use, teams are cutting impact-assessment time from days to hours, reducing the manual effort involved in keeping large documentation sets current while maintaining human oversight of consequential changes.

Tridion Agent and Tridion Connect are now in public preview, ahead of planned general availability in 2027. Register your interest now.

About us

RWS is a global AI solutions company empowering the world's most trusted enterprise AI.

Our proprietary Cultural Intelligence Layer, powered by 250,000+ data specialists, cultural and language experts and deep domain professionals, backed by 47+ patents, makes enterprise AI culturally fluent, contextually accurate and secure, ensuring every interaction reflects a brand's tone, context and customer values.

Through our Generate, Transform, and Protect segments, we deliver intelligent content, enterprise knowledge, large-scale localization, and IP protection for global growth. Trusted by 80+ of the world's top 100 brands, RWS provides the confidence, governance and expertise organizations need to deploy AI safely, responsibly and at scale. Headquartered in the UK, RWS is listed on AIM.

More information: rws.com.

SOURCE RWS

Share this article

Opening X-Net to Banks with Diverse Cooperation Models

XIAMEN, China, Sept. 16, 2026 /PRNewswire/ -- The 26th China International Fair for Investment and Trade (CIFIT) was held in Xiamen last week. XTransfer, a leading global B2B cross-border trade payment platform, signed strategic cooperation agreements with China ZheShang Bank (CZ Bank) and Industrial Bank Co., Ltd. (CIB) during the event. The partnerships target key cross-border finance scenarios, including minor-currency collection in emerging markets and RMB conversion and withdrawal, using fintech to help foreign trade companies overcome FX settlement and remittance difficulties.

Hosted by China's Ministry of Commerce, this year's CIFIT saw CIPS establish a cross-border bank–enterprise cooperation zone for the first time, bringing together over 70 Chinese and foreign banks to showcase cross-border RMB services. XTransfer is signing agreements in the CIPS zone, underscoring its coordination with national-level financial infrastructure.

Bank Partnerships Address FX Pain Points

During the exhibition, XTransfer and CZ Bank jointly announced an all-currency settlement solution. Powered by XTransfer's X-Net global local-collection network, it helps CZ Bank's export clients collect payments in local currencies across global markets. The service focuses on Africa, the Middle East, and Latin America, addressing pain points such as local buyers being unable to pay in their own currency and long fund arrival times.

XTransfer and CIB also signed a strategic cooperation agreement to deepen collaboration in cross-border RMB clearing and minor-currency collection, improving the efficiency and coverage of RMB conversion and withdrawal. The service can handle the declaration of international receipts on behalf of foreign trade companies during the trade settlement process, convert funds, and credit them directly to onshore corporate accounts without affecting export tax rebates, significantly enhancing convenience for foreign trade firms.

Bill Deng, Founder and CEO of XTransfer, said, "The partnerships cover everything from collecting minor currencies in emerging markets to onshore RMB conversion and withdrawals, creating an end-to-end funding chain so that 'minor currencies' no longer become a major headache on the road to global expansion." He added, "XTransfer looks forward to working with more financial institution partners to integrate fintech with the real economy and support Chinese foreign trade companies' globalisation."

Opening X-Net to Banks with Diverse Cooperation Models

At CIFIT, XTransfer showcased its globally unified B2B cross-border trade settlement network and risk-control system, X-Net, presenting multiple cooperation models for financial institution partners.

For many years, banks have provided XTransfer with access to capabilities such as domestic collections, domestic payments, FX conversion, and cross-border compliance reporting. Today, banks can directly leverage X-Net's cross-border payment and local collection capabilities to serve their own customers, allowing the network capabilities built through long-term collaboration to benefit the banks' own businesses.

Specifically, to address the challenge faced by banks' exporter clients in collecting payments in emerging markets, XTransfer has launched a dedicated "Bank Minor-Currency Collection Solution", opening up the X-Net global local collection network to banks in China and worldwide. This helps export clients collect minor-currency payments from emerging markets and repatriate funds.

Banks worldwide can also use X-Net to provide importers with fast, compliant payment services to China, supporting settlement in multiple currencies such as the U.S. dollar and the Chinese yuan, as well as helping local importer companies pay overseas suppliers in local currencies.

SOURCE XTransfer

Share this article

INDEPENDENCE, Ohio, Sept. 16, 2026 /PRNewswire/ -- Today, SellYourWay.org announces the launch of a new, dynamic feature on their website, defining the Certified Business Intermediary® (CBI) designation. This interactive tool educates small business owners on the advantages of working with these highly qualified and ethical Business Brokers when preparing to sell their business. This new resource emphasizes the benefits of selecting a CBI® — a professional who has met educational and performance requirements — and remains committed to ongoing education on industry trends, standards, and best practices. SellYourWay.org is a website for small business owners powered by The International Business Brokers Association® (IBBA), the largest international not-for-profit association for business brokers.

When a small business owner sells a business, the very-best representation comes from a Business Broker who has achieved the Certified Business Intermediary® (CBI) designation.

The new, interactive feature on sellyourway.org breaks the designation down into six qualifications that business owners should look for in their Business Broker:

These rigorous education, examination and experience requirements help ensure CBI®s stay current on the latest market trends — giving business owners greater confidence when choosing a qualified professional to value, market and sell their businesses.

"For most business owners, selling their businesses is a once-in-a-lifetime event. Working with a CBI® ensures that the entire process — from valuation to negotiation to final sale — is executed with expertise and integrity. This partnership not only improves the odds of a successful close, but also provides sellers with peace of mind, knowing that an experienced professional is guiding them through every step of the transaction." - Emily Bowler, Executive Director, IBBA

Access actionable insights to prepare for the sale of your business on SellYourWay.Org.

About SellYourWay.Org

The mission of SellYourWay.org is to educate small business owners and the general public about the business sales process and the services that business brokers provide. The resources available on the site provide information to help business owners prepare for the successful sale of their businesses.

About the International Business Brokers Association®

Formed in 1984 and with more than 3,000 members, the International Business Brokers Association® (IBBA) is the largest international not for profit association for business brokers. The association provides business brokers with education, free benefits, conferences, professional designations, support programs and networking opportunities, and awards the Certified Business Intermediary (CBI)® designation to qualifying business brokers. To learn more, contact the IBBA directly at [email protected].

[Social Media Handles]

Facebook - https://www.facebook.com/profile.php?id=61558428497579

Twitter - https://twitter.com/_SellYourWay

Instagram - https://www.instagram.com/_sellyourway/

LinkedIn - https://www.linkedin.com/company/103495058/admin/feed/posts/

Pinterest - https://pin.it/47ytLpWzo 

SOURCE Sell Your Way

Share this article

Medius Appoints Maartje van Zadelhoff as Sales Director, Benelux

Seasoned SaaS sales leader brings 15+ years of regional expertise to drive AP automation growth across the Benelux market

AMSTERDAM, Netherlands, Sept. 16, 2026 /PRNewswire/ -- Medius, a leading provider of AP automation and spend management solutions, today announced the appointment of Maartje van Zadelhoff as Sales Director for the Benelux region. In this role, she will lead Medius's commercial sales strategy and team across the Netherlands, Belgium, and Luxembourg.

Van Zadelhoff joins Medius from Freshworks Technologies, where she served as Senior Sales Manager across Northern and Eastern Europe, delivering strong growth across the region. Prior to that, she spent five years at UiPath, rising to Regional Vice President of Commercial Sales for Benelux and the Nordics.

Her background spans enterprise SaaS, RPA, and financial process automation which is well-aligned with Medius's mission to help finance teams operate with greater efficiency and control.

Ash Botten, EVP of EMEA Sales, Medius, comments: "Maartje joins Medius at a time when we see growing demand for real-time insights, control, and fraud prevention. There's never been a more important time to deliver solutions that help finance teams lead with confidence. Her track record as a commercial leader will be instrumental in driving our growth in Benelux. Her deep relationships and experience across the Benelux market make her exceptionally well-placed to accelerate our momentum there."

For more information, please contact: Iraj Gillani at Fight or Flight [email protected] / [email protected]

This information was brought to you by Cision http://news.cision.com

Share this article

MDA SPACE ANNOUNCES END-TO-END MDA CHORUS™ PRODUCT PORTFOLIO IN ADVANCE OF CONSTELLATION LAUNCH

MDA CHORUS™ COMMAND, MDA CHORUS™ COMMAND PRO and MDA CHORUS™ INTELLIGENCE provide customers end-to-end control of their Earth observation workflow

TORONTO and PARIS, Sept. 16, 2026 /PRNewswire/ -- MDA Space Ltd. (TSX: MDA) (NYSE: MDA), a trusted mission partner to the global defence and space industry, unveiled today at the World Space Business Week conference the end-to-end MDA CHORUS™ Earth observation (EO) product portfolio. The introduction of the full portfolio precedes the highly anticipated launch of the MDA CHORUS™ constellation later this year.

Leveraging the company's next generation MDA CHORUS™ constellation, the introduction of MDA CHORUS™ COMMAND, MDA CHORUS™ COMMAND PRO and MDA CHORUS™ INTELLIGENCE offers customers a complete portfolio to customize, manage and control their geointelligence workflow — from data collection planning to tasking to decision-ready insight.

"Earth observation at MDA Space has always meant more than building world-class spacecraft. We have spent decades turning synthetic aperture radar (SAR) data into intelligence products for maritime, defence and critical infrastructure monitoring" said Mike Greenley, CEO of MDA Space. "With this new expanded MDA CHORUS™ product line, we have taken that same heritage and built it into a user-friendly and complete product system that customers can directly access, task, and grow with."

A Complete Earth Observation System, Built Around the Customer

Incorporating constellation assets, ground infrastructure, archive access and analytics, the MDA CHORUS™ product portfolio now provides customers a complete unified commercial architecture, including:

MDA CHORUS™ COMMAND:

The operational entry point for the ecosystem, this intuitive platform allows customers to search the archive, define areas of interest, set imaging priorities, tip and cue, and schedule acquisitions. It includes Application Programming Interface (API) connectors, guides and a knowledge hub, streamlining and consolidating customer access to MDA CHORUS™.

MDA CHORUS™ COMMAND PRO:

Enables maximum customer control of the system by integrating an MDA CHORUS™ regional ground station directly into a customer's operations, providing direct downlink and near-real-time local processing — eliminating latency and delivering the independence that defence and critical infrastructure customers require.

MDA CHORUS™ INTELLIGENCE:

A comprehensive suite of geointelligence data and analytics products leveraging decades of SAR expertise and spanning maritime awareness, vessel detection, oil-on-water, ground deformation and energy infrastructure monitoring. The suite draws on SAR satellite images and telemetry, value-added geographic information system (GIS) data files and reports, and integrated third-party data products.

MDA CHORUS™ Constellation:

Powering the portfolio is the MDA CHORUS™ Constellation, a three satellite system fully integrating two new spacecraft — one X-band, one C-band — delivering high-revisit, all-weather imaging on orbit, anchored by RADARSAT-2, the company's world-leading EO platform already on orbit.

Today's product announcement builds on the official opening last month of the company's new MDA CHORUS™ Control Centre, marking another operational readiness milestone as momentum builds for the constellation's launch in late 2026.

For more information, visit mda.space/chorus

FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the company's current expectations regarding future events. Such forward-looking information includes, but is not limited to, the capabilities and functionality of the MDA CHORUS™ product line and the ultimate use of the MDA CHORUS™ product line by customers. Forward-looking statements are based on certain assumptions and analyses made by MDA Space in light of management's experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties and other factors which may cause the actual results, performance or achievements of MDA Space to differ materially from those anticipated in such forward-looking statements for a variety of reasons, including without limitation the risks and uncertainties detailed under the "Risk Factors" section of MDA Space's annual information form dated March 4, 2026.

Although MDA Space believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect and there can be no assurance that actual results will be consistent with the forward-looking statements. There are a number of additional risks and uncertainties affecting or that could affect MDA Space, which could cause actual results and developments to differ materially from those described in, expressed or implied by these forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements or information included within this press release. These forward-looking statements speak only as of the date of this news release. Except as required by law, MDA Space is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ABOUT MDA SPACE

Building the space between proven and possible, MDA Space (TSX:MDA) (NYSE:MDA) is a trusted mission partner to the global defence and space industry. A robotics, satellite systems and geointelligence pioneer with a 55-year+ story of world firsts and more than 450 missions, MDA Space is a global leader in communications satellites, Earth and space observation, and space exploration and infrastructure. The global MDA Space team of more than 4,000 space experts has the knowledge and know-how to turn an audacious customer vision into an achievable mission — bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For more information, visit mda.space.

SOCIAL MEDIA

LinkedIn: LinkedIn.com/company/MDAspace 

X: X.com/MDA_space 

Facebook: Facebook.com/MDAspace

YouTube: YouTube.com/c/MDAspace

Instagram: Instagram.com/MDA_space 

SOURCE MDA Space

Share this article

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

- Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW)

- Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks in adults and launched in over 30 countries worldwide

- Authorization supported by the Phase III SUNRISE trial and the SUNSET long-term extension study in Japanese patients

- Building on 25 years of commitment to patients and brain health in Japan, the approval paves the way for Lundbeck's first launch in Japan as Marketing Authorization holder, enabling Lundbeck to operate independently on the Japanese market

VALBY, Denmark, Sept. 16, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has granted marketing authorization for eptinezumab for the prevention of migraine attacks in adults, marking an important milestone for patients in Japan and for Lundbeck's continued growth in Asia.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe headache often accompanied by nausea, vomiting, and sensitivity to light and sound. In Japan, migraine affects an estimated 8.4%–11.0% of the population1 and is the fourth leading cause of years lived with disability.2 Beyond the physical symptoms, migraine significantly affects daily functioning, quality of life, work productivity and life course.2 Migraine is estimated to cost the Japanese economy US$ 3 billion every year in lost productivity.3

"This approval represents a significant advancement for people living with migraine in Japan, where the disease continues to place a substantial burden on patients, families, and society," said Tarek Samad, EVP and Head of Research and Development at Lundbeck. "Eptinezumab is a differentiated IV CGRP-targeted therapy that offers adults living with migraine an important new treatment option, and we are proud to bring this innovative medicine to patients in Japan. This approval also marks an exciting new chapter for Lundbeck Japan as we prepare for our first independent launch, building on 25 years of commitment to patients and brain health in the country."

Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and was developed for IV administration as a preventive treatment for migraine.

The Japanese marketing authorization is supported by the global clinical development program for eptinezumab, including the Phase III PROMISE-1, PROMISE-2 and DELIVER trials, together with data from the Phase III SUNRISE trial, which evaluated efficacy and safety in a predominantly Asian population with chronic migraine.4 The application was further supported by the Phase III SUNSET long-term extension study conducted specifically in Japanese patients to evaluate the long-term safety of eptinezumab.2

Eptinezumab was first approved by the U.S. Food and Drug Administration in 2020 for the preventive treatment of migraine in adults, followed by additional approvals including in the European Union and most recently South Korea. It has since been launched in more than 30 markets worldwide.

About migraine

Migraine is a complex and disabling neurological disease characterized by recurrent attacks of severe headache typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound. Not only is headache painful, but migraine also imposes both a social and financial burden. Migraine can have a profound impact on daily functioning, work productivity, family and social relationships and quality of life.

Migraine is one of the most prevalent neurological diseases worldwide and remains a leading cause of disability, particularly among people under the age of 50.5,6 As migraine frequency and severity increase, attacks may become harder to control, contributing to greater disease burden and, without appropriate preventive management, progression to chronic migraine.7

About Vyepti® (eptinezumab)

Eptinezumab is a humanized mAb that binds to CGRP which was designed for IV administration. The efficacy and safety of eptinezumab were evaluated in two Phase III clinical trials, PROMISE-1 in episodic migraine8 and PROMISE-2 in chronic migraine.9 In both trials, eptinezumab met its primary endpoint of decrease in monthly migraine days (MMDs) over weeks 1-12.

The safety of eptinezumab has been evaluated in more than 5,000 adult patients with migraine who received at least one dose. Common adverse reactions in the placebo-controlled clinical trials for the preventive treatment of migraine were hypersensitivity and infusion-related reactions.

VYEPTI® (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. In Japan, eptinezumab is approved for the prevention of migraine attacks in adults. Today, eptinezumab is launched in more than 30 markets worldwide.

Contacts

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References:

- Sakai F, Igarashi H. Cephalalgia. 1997;17(1):15-22

- Takeshima T, et al. J Headache Pain. 2025;26(1):275

- Sakai F (2010) Olesen J, Ramadan N (eds) Headache care, research and education worldwide, vol 17. Oxford University Press, New York, pp 35–40

- Yu S, et al. Cephalalgia. 2025;45(10):3331024251386095

- Steiner TJ, et al. J Headache Pain. 2018;19(1):17

- Leonardi M, et al. J Headache Pain. 2005; 6(6):429– 440

- Lipton RB, et al. J Neurol. 2023;270(12);5692–5710

- Ashina M, et al. Cephalalgia. 2020;40(3):241-254

- Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377

CONTACT:

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

[email protected] 

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

Redefining Community Medicine Beyond the City Limits: West Ascension Parish Hospital Service District Examined on "All Access hosted by Andy Garcia"

Exploring a national movement toward localized care, an upcoming Public Television broadcast demonstrates how small-town medical facilities deliver comprehensive clinical excellence.

NEW ORLEANS, Sept. 16, 2026 /PRNewswire/ -- "All Access hosted by Andy Garcia" recently selected West Ascension Parish Hospital Service District for an educational feature exploring rural health solutions. Following successful on-location production in July 2026, the documentary segment explores how designated Critical Access Hospitals serve as essential lifelines for local families. Public Television viewers will learn how cultivating open workplace dialogue and modernizing daily operations allow community health centers to deliver high-reliability medical care without requiring patients to travel far from their homes.

The segment highlights how analyzing qualitative staff feedback and broader regional clinical outcomes informs structural change. West Ascension Parish Hospital Service District illustrates how tracking frontline workflow metrics enables physicians and nurses to streamline patient handoffs and reduce system friction. By utilizing diverse health data gathered across various community touchpoints, the broadcast illustrates how data-informed leadership creates adaptable care models that elevate patient safety and support sustainable community growth.

"Being featured on All Access is an opportunity to share what we have always known—rural healthcare does not mean limited healthcare," said Shelton Anthony, CEO of West Ascension Parish Hospital. "This documentary shines a light on the vital role community hospitals play in the health and future of rural communities. At West Ascension Parish Hospital, we are moving forward with purpose—investing in our people, strengthening our services and embracing technology that enhances the patient experience. Our goal is simple: to ensure every person we serve can receive trusted, high-quality care right here at home. We are proud to show a national audience how community hospitals can provide exceptional, compassionate care while ensuring patients have access to the services they need close to home."

Traditional healthcare delivery models often concentrate specialized medical services within dense metropolitan hubs, leaving smaller communities vulnerable to reduced access and delayed treatments. Reversing this trend requires recognizing that high-quality, life-saving care belongs in every neighborhood. When regional facilities invest in workforce development, modern digital tools, and expanded outpatient services, they transform from basic emergency stops into complete health hubs. Empowering local medical teams fosters deep patient trust and creates a sustainable environment where families receive competent, compassionate care within their own neighborhoods.

The rapid implementation of machine-learning algorithms and electronic health platforms introduces serious concerns regarding data integrity in small-town medicine. Opaque algorithms frequently process patient information without providing clinical teams visibility into how software recommendations are generated. When automated platforms depend on limited or biased training sets, they risk misinterpreting community health trends or misallocating critical clinical resources. Safeguarding patient outcomes requires software architects to build open, fully auditable digital tools trained on diverse demographic data, ensuring computational systems enhance human expertise without compromising individualized care.

About "All Access hosted by Andy Garcia": "All Access hosted by Andy Garcia" is an award-winning educational documentary series distributed across Public Television stations nationwide. The program offers viewers insightful coverage on groundbreaking developments in medicine, science, technology, and culture, hosted by acclaimed actor Andy Garcia. To learn more about the series and its commitment to educational broadcasting, visit allaccessptv.com.

About West Ascension Parish Hospital Service District: West Ascension Parish Hospital Service District operates as a dedicated Critical Access Hospital providing essential medical services to Donaldsonville and surrounding communities. Through comprehensive emergency care, inpatient treatment, and expanded outpatient specialties, the facility delivers high-quality, human-centered medicine close to home. To learn more about local health services and community care initiatives, visit westaph.org.

SOURCE All Access

Share this article

ROHM Launches MOSFET Featuring Wide-SOA for Automotive Safety Functions and Protection Circuits

KYOTO, Japan, Sept. 16, 2026 /PRNewswire/ -- ROHM Co., Ltd. has developed the RS4P063BPHZG, a 100V MOSFET optimized for automotive safety functions and protection circuits. The new product achieves a Wide-SOA (Safe Operating Area) across a broad voltage range in the standard HPLF5060 (5060-size) package widely used in automotive applications. By incorporating a design that effectively suppresses secondary breakdown, it delivers approximately five times the SOA tolerance of standard equivalent-sized products under VDS=100V and PW=100 microseconds. This contributes to greater reliability in automotive applications subject to momentary high-power loads, including airbag inflator ignition circuits and seat belt pretensioner drive circuits.

RS4P063BPHZG product page: https://www.rohm.com/products/mosfets/automotive/single-nch/rs4p063bphzg-product

Figures: Product features

https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202609045332/_prw_PI1fl_c7f2yHyJ.jpg 

Adopting the standard 5060-size package also simplifies replacement evaluation with existing layouts, helping reduce the workload and costs associated with design changes.

Recent advances in vehicle electrification are increasing demand for automotive systems that support higher voltages and currents. In particular, safety functions and protection circuits may experience momentary high-power loads during abnormal or emergency conditions, requiring the MOSFETs that drive them to provide high SOA capability.

ROHM has established a strong track record of providing Wide-SOA products for AI servers and industrial power supplies, including products that have been selected as recommended components by a global cloud platform provider. The RS4P063BPHZG brings the same technologies and expertise to the automotive field.

ROHM is developing automotive Wide-SOA MOSFETs in the HPLF8080 (8.0 x 8.0 mm) and TOLG (TO-Leaded with Gullwing, 9.9 x 11.7 mm) packages as well. Going forward, ROHM will continue expanding its portfolio for automotive safety functions and protection circuits.

Figures: Product lineup

https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202609045332/_prw_PI2fl_y19ILm7M.jpg 

Application examples

- Airbag inflator ignition circuits

- Seat belt pretensioner drive circuits

- Pyro-fuse drive circuits for battery cutoff

- Other automotive safety functions and protection circuits exposed to short-duration high-current and high-voltage stress

News release: https://www.rohm.com/news-detail?news-title=2026-09-15_news_mosfet&defaultGroupId=false

About ROHM: https://kyodonewsprwire.jp/attach/202609045332-O1-h0a28HjJ.pdf

Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202609045332/_prw_PI3fl_jv5oqdOQ.jpg

Official website: https://www.rohm.com/

SOURCE ROHM Co., Ltd.

Share this article